Arca
Skip to content
Tools
Tools

CD40: Tumor necrosis factor receptor superfamily member 5

Receptor for TNFSF5/CD40LG.

  • Drugs that act on it: 11
  • Approved: 0
  • In phases 1 to 3: 11
  • Sponsors: 9

Who is on it, and how far along

Every drug ChEMBL records acting on CD40, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 8
  • Other 3

Approved0

    Phase 30

      Phase 211

      • CDX-1140
      • CD40 ligand
      • PG-102
      • Selicrelumab
      • Sotigalimab
      • Bleselumab
      • Dacetuzumab
      • Giloralimab
      • Iscalimab
      • Lucatumumab
      • Teneliximab

      Phase 10

        Sponsors

        Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

        • Apexigen America, Inc.19%
        • Celldex Therapeutics19%

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        CDX-1140Phase 2Celldex TherapeuticsOtherAgonistTumor necrosis factor receptor superfamily member 5 agonist7
        CD40 ligandPhase 2MemgenOtherAgonistTumor necrosis factor receptor superfamily member 5 agonist4
        PG-102Phase 2Rani TherapeuticsOtherInhibitorTumor necrosis factor receptor superfamily member 5 inhibitor4
        SelicrelumabPhase 2RocheAntibodyAgonistTumor necrosis factor receptor superfamily member 5 agonist1
        SotigalimabPhase 2Apexigen America, Inc.AntibodyAgonistTumor necrosis factor receptor superfamily member 5 agonist1
        BleselumabPhase 2Astellas PharmaAntibodyInhibitorTumor necrosis factor receptor superfamily member 5 inhibitor0
        DacetuzumabPhase 2PfizerAntibodyInhibitorTumor necrosis factor receptor superfamily member 5 inhibitor0
        GiloralimabPhase 2AbbVieAntibodyAgonistTumor necrosis factor receptor superfamily member 5 agonist0
        IscalimabPhase 2Novartis PharmaceuticalsAntibodyInhibitorTumor necrosis factor receptor superfamily member 5 inhibitor0
        LucatumumabPhase 2Novartis PharmaceuticalsAntibodyAntagonistTumor necrosis factor receptor superfamily member 5 antagonist0
        TeneliximabPhase 2—AntibodyPartial agonistTumor necrosis factor receptor superfamily member 5 partial agonist0

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 15 in all, from ClinicalTrials.gov.
        Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes MellitusPG-102Phase 2Not yet recruitingProGen. Co., Ltd.Jul 1, 2026
        Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes MellitusPG-102Phase 2Not yet recruitingProGen. Co., Ltd.Sep 23, 2025
        Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerCDX-1140Phase 2RecruitingNational Cancer Institute (NCI)May 20, 2025
        An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.PG-102Phase 1RecruitingRANI TherapeuticsMar 24, 2025
        Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 DiabetesPG-102Phase 2Active, not recruitingProGen. Co., Ltd.Dec 2, 2024
        Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)CD40 ligandPhase 1 / Phase 2Active, not recruitingUniversity of ChicagoMar 12, 2024
        A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)CDX-1140Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)May 9, 2023
        Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)CDX-1140Phase 1Active, not recruitingProvidence Health & ServicesApr 27, 2022
        Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian CancerCDX-1140Phase 2RecruitingRoswell Park Cancer InstituteFeb 9, 2022
        MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid TumorsCD40 ligandPhase 1RecruitingMemgen, Inc.Oct 13, 2021
        CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast CancerCD40 ligand, CDX-1140Phase 1RecruitingUniversity of Texas Southwestern Medical CenterSep 1, 2021
        In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid TumorsCD40 ligand, CDX-1140Phase 1Active, not recruitingUniversity of Southern CaliforniaNov 4, 2020
        Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)CDX-1140Phase 1Active, not recruitingProvidence Health & ServicesAug 20, 2020
        A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerSelicrelumabPhase 1 / Phase 2RecruitingHoffmann-La RocheFeb 6, 2018
        Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal CancerSotigalimabPhase 1Active, not recruitingM.D. Anderson Cancer CenterNov 9, 2015

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Hyper-IgM syndrome type 30.79
        • Crohn disease0.50
        • Thyrotoxicosis0.46
        • Kawasaki disease0.45
        • Mathematical ability0.45
        • ACPA-positive rheumatoid arthritis0.45

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1250358, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P25942, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.